Mary Caffrey

Questions arise around equity and revenue challenges.

Katalin Karikó, PhD, and Drew Weissman, MD, PhD, win Nobel Prize for discoveries in the area of nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.

Prescription benefits consultant Chris Robbins, chief executive of cer of Arxcel, describes the finger-pointing in Congress over lowering drug costs this way: “If it weren’t so true, it might be almost humorous.”

Ongoing access to diabetes self-management education and support, and promoting good medication adherence are among the keys to managing high blood glucose in patients with type 2 diabetes.

FDA has granted priority review designation for Merck’s request for a supplemental biologics license application for pembrolizumab to treat Merkel cell carcinoma, a rare skin cancer.

Patients with diabetes taking canagliflozin achieved better glycemic control, were less likely to stop taking the medication, and were less likely to switch to another drug.

Besides tracking the Healthy Days metric, Humana has focused interventions around social determinants of health: food insecurity, loneliness, and social isolation.

The results of the ODYSSEY-Diabetes trials focused on alirocumab, an approved monoclonal antibody that prevents PCSK-9 protein from impairing the liver’s receptors, and that antibody's effect on type 2 diabetes (T2D).

While Medicare awaits its DPP rollout, it exists already through many outlets nationally.

Symposium on PCSK9 inhibitors in treatment of type 1 diabetes highlighted at 77th Scientific Sessions of the ADA.

Tresiba found to offer patients with type 2 diabetes (T2D) a lower risk of severe hypoglycemia.

The enzyme that affects the body's ability to process LDL cholesterol was found to be correlated with A1C levels. A symposium on the topic will be part of this weekend's 77th Scientific Sessions of the American Diabetes Association.

Some high-risk patients have better than expected outcomes due to frequent follow-up by physicians.

The study finds that this biomarker can show which patients may develop heart disease even if they have no current blockage or elevated cholesterol levels.

The 12-biomarker test is gaining acceptance among rheumatologists and was recently added to a clinical guideline.